{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:09:39Z","timestamp":1781824179762,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canrad.2025.104778","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T13:35:23Z","timestamp":1763991323000},"page":"104778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reirradiation of prostate, gynaecologic and pelvic tumours, suggestions from the Recommendations Commission of the Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique"],"prefix":"10.1016","volume":"29","author":[{"given":"Yuedan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Escande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Chargari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Ayadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Latorzeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Guimas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Beddok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7\u20138","key":"10.1016\/j.canrad.2025.104778_bib0290","doi-asserted-by":"crossref","first-page":"104777","DOI":"10.1016\/j.canrad.2025.104777","article-title":"External beam radiotherapy for prostatic cancers: 2025 update","volume":"29","author":"Latorzeff","year":"2025","journal-title":"Cancer Radiother"},{"issue":"4","key":"10.1016\/j.canrad.2025.104778_bib0295","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.juro.2007.11.063","article-title":"Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer","volume":"179","author":"Zelefsky","year":"2008","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104778_bib0300","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, Version 2.2019 NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.canrad.2025.104778_bib0305","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104778_bib0310","first-page":"100806","article-title":"Reirradiation to the prostate using stereotactic body radiotherapy (SBRT) after initial definitive radiotherapy - A systematic review and meta-analysis of recent trials","volume":"48","author":"Schr\u00f6der","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104778_bib0315","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euo.2023.01.009","article-title":"The safety and efficacy of salvage stereotactic radiation therapy in patients with intraprostatic tumor recurrence after previous external radiation therapy: phase 1 results from the Getug-Afu 31 study","volume":"6","author":"Pasquier","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.canrad.2025.104778_bib0320","doi-asserted-by":"crossref","first-page":"102206","DOI":"10.1016\/j.ctrv.2021.102206","article-title":"Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus","volume":"98","author":"Jereczek-Fossa","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.canrad.2025.104778_bib0325","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13014-017-0789-9","article-title":"Salvage prostate reirradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy","volume":"12","author":"Mbeutcha","year":"2017","journal-title":"Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104778_bib0330","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ijrobp.2010.11.031","article-title":"Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer","volume":"82","author":"Jereczek-Fossa","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.canrad.2025.104778_bib0335","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.23.01391","article-title":"Salvage reirradiation for locally recurrent prostate cancer: results from a prospective study with 7.2 years of follow-up","volume":"42","author":"Ekanger","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104778_bib0340","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.adro.2020.04.022","article-title":"A novel salvage option for local failure in prostate cancer, reirradiation using external beam or stereotactic radiation therapy: systematic review and meta-analysis","volume":"5","author":"Corkum","year":"2020","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104778_bib0345","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104778_bib0350","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijrobp.2019.10.014","article-title":"Retreatment for local recurrence of prostatic carcinoma after prior therapeutic irradiation: efficacy and toxicity of HDR-like SBRT","volume":"106","author":"Fuller","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104778_bib0355","doi-asserted-by":"crossref","first-page":"109672","DOI":"10.1016\/j.radonc.2023.109672","article-title":"Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus study","volume":"184","author":"Corkum","year":"2023","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104778_bib0360","doi-asserted-by":"crossref","first-page":"e615e623","DOI":"10.1016\/j.prro.2015.04.009","article-title":"High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment","volume":"5","author":"Fuller","year":"2015","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104778_bib0365","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ijrobp.2016.05.024","article-title":"Reirradiation of prostate cancer local failures after previous curative radiation therapy: long-term outcome and tolerance","volume":"96","author":"Zilli","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.canrad.2025.104778_bib0370","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3390\/cancers14081943","article-title":"Magnetic resonance-guided reirradiation for local recurrence within the prostate or in the prostate bed: one-year clinical results of a prospective registry study","volume":"14","author":"Michalet","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.canrad.2025.104778_bib0380","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijrobp.2019.07.012","article-title":"Salvage stereotactic body radiation therapy for local prostate cancer recurrence after radiation therapy: a retrospective multicenter study of the Getug","volume":"105","author":"Pasquier","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104778_bib0385","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2021.12.047","article-title":"UROGEC group of Gec ESTRO with endorsement by the European Association of Urology, Gec-ESTRO ACROP prostate brachytherapy guidelines","volume":"167","author":"Henry","year":"2022","journal-title":"Radiother Oncol"},{"issue":"8","key":"10.1016\/j.canrad.2025.104778_bib0375","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026666","article-title":"G\u00e9tug-Afu 31: a phase I\/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol","volume":"9","author":"Pasquier","year":"2019","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.canrad.2025.104778_bib0390","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.brachy.2014.06.005","article-title":"Reirradiation using high-dose-rate brachytherapy in recurrent carcinoma of uterine cervix","volume":"13","author":"Mahantshetty","year":"2014","journal-title":"Brachytherapy"},{"issue":"5","key":"10.1016\/j.canrad.2025.104778_bib0395","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2020.07.014","article-title":"Interim results of a prospective prostate-specific membrane antigen-directed focal stereotactic reirradiation trial for locally recurrent prostate cancer","volume":"108","author":"Bergamin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.canrad.2025.104778_bib0400","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.euo.2023.03.005","article-title":"Salvage stereotactic reirradiation for local recurrence in the prostatic bed after prostatectomy: a retrospective multicenter study","volume":"6","author":"Archer","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104778_bib0405","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3390\/curroncol30010088","article-title":"Different reirradiation techniques after breast-conserving surgery for recurrent or new primary breast cancer","volume":"30","author":"Abeloos","year":"2023","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104778_bib0410","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ijrobp.2014.10.053","article-title":"MRI-guided high-dose-rate intracavitary brachytherapy for treatment of cervical cancer: the University of Pittsburgh experience","volume":"91","author":"Gill","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.canrad.2025.104778_bib0415","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-018-0310-8","article-title":"Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy","volume":"119","author":"Wortman","year":"2018","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.canrad.2025.104778_bib0420","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.radonc.2011.08.014","article-title":"Local recurrences in cervical cancer patients in the setting of image-guided brachytherapy: a comparison of spatial dose distribution within a matched-pair analysis","volume":"100","author":"Schmid","year":"2011","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104778_bib0425","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1470-2045(15)00534-3","article-title":"Hyperbaric oxygen therapy for radiation-induced injury: evidence is needed","volume":"17","author":"Creutzberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104778_bib0430","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.brachy.2017.11.011","article-title":"Image-guided interstitial high-dose-rate brachytherapy for locally recurrent uterine cervical cancer: a single-institution study","volume":"17","author":"Umezawa","year":"2018","journal-title":"Brachytherapy"},{"issue":"3","key":"10.1016\/j.canrad.2025.104778_bib0435","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ygyno.2005.11.004","article-title":"Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence","volume":"101","author":"Petignat","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104778_bib0440","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/PGP.0b013e31829c6757","article-title":"Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; vaginal versus other sites","volume":"33","author":"Moschiano","year":"2014","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104778_bib0445","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2006.04.037","article-title":"Magnetic resonance-guided interstitial therapy for vaginal recurrence of endometrial cancer","volume":"66","author":"Viswanathan","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.canrad.2025.104778_bib0450","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2018.12.022","article-title":"Outcomes after definitive re-irradiation with 3D brachytherapy with or without external beam radiation therapy for vaginal recurrence of endometrial cancer","volume":"152","author":"Ling","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104778_bib0455","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.brachy.2017.07.007","article-title":"MR- versus CT-based high-dose-rate interstitial brachytherapy for vaginal recurrence of endometrial cancer","volume":"16","author":"Kamran","year":"2017","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.canrad.2025.104778_bib0460","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brachy.2019.11.008","article-title":"American Brachytherapy Society working group report on the patterns of care and a literature review of reirradiation for gynecologic cancers","volume":"19","author":"Sturdza","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.canrad.2025.104778_bib0465","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2021.09.010","article-title":"An international Delphi consensus for pelvic stereotactic ablative radiotherapy reirradiation","volume":"164","author":"Slevin","year":"2021","journal-title":"Radiother Oncol"},{"issue":"7\u20138","key":"10.1016\/j.canrad.2025.104778_bib0470","doi-asserted-by":"crossref","first-page":"104753","DOI":"10.1016\/j.canrad.2025.104753","article-title":"Radiotherapy and brachytherapy for cervical cancer: recommendations of the soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique","volume":"29","author":"Chargari","year":"2025","journal-title":"Cancer Radiother"},{"issue":"3","key":"10.1016\/j.canrad.2025.104778_bib0475","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2022.09.072","article-title":"GEC-ESTRO (ACROP)-ABS-CBG consensus brachytherapy target definition guidelines for recurrent endometrial and cervical tumors in the vagina","volume":"115","author":"Kamrava","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.canrad.2025.104778_bib0480","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.radonc.2004.12.015","article-title":"Recommendations from Gynaecological (GYN) Gec-ESTRO Working group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV","volume":"74","author":"Haie-M\u00e9der","year":"2005","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104778_bib0485","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brachy.2011.07.002","article-title":"American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy","volume":"11","author":"Viswanathan","year":"2012","journal-title":"Brachytherapy"},{"issue":"3","key":"10.1016\/j.canrad.2025.104778_bib0490","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.radonc.2016.06.006","article-title":"Dose\u2013volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study","volume":"120","author":"Mazeron","year":"2016","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104778_bib0495","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ijrobp.2018.02.004","article-title":"Risk of late urinary complications following image guided adaptive brachytherapy for locally advanced cervical cancer: refining bladder dose\u2013volume parameters","volume":"101","author":"Manea","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.canrad.2025.104778_bib0500","first-page":"2413","article-title":"Salvage high-dose-rate interstitial brachytherapy for pelvic recurrent cervical carcinoma after hysterectomy","volume":"36","author":"Murakami","year":"2016","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.canrad.2025.104778_bib0505","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.brachy.2015.02.195","article-title":"Treatment results of image-guided high-dose-rate interstitial brachytherapy for pelvic recurrence of uterine cancer","volume":"14","author":"Yoshida","year":"2015","journal-title":"Brachytherapy"},{"key":"10.1016\/j.canrad.2025.104778_bib0510","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13014-014-0230-6","article-title":"Oligometastasis and oligorecurrence: more than a mirage","volume":"9","author":"Huang","year":"2014","journal-title":"Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104778_bib0515","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jjco\/hyp167","article-title":"Oligometastases and oligorecurrence: the new era of cancer therapy","volume":"40","author":"Niibe","year":"2010","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"10.1016\/j.canrad.2025.104778_bib0520","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/annonc\/mds053","article-title":"Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)","volume":"23","author":"Ruers","year":"2012","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.canrad.2025.104778_bib0525","doi-asserted-by":"crossref","first-page":"djx015","DOI":"10.1093\/jnci\/djx015","article-title":"Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial","volume":"109","author":"Ruers","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.canrad.2025.104778_bib0530","doi-asserted-by":"crossref","first-page":"znad449","DOI":"10.1093\/bjs\/znad449","article-title":"Lateral pelvic lymph nodes in rectal cancer: a multidisciplinary team effort is needed to prevent local recurrence","volume":"111","author":"Kusters","year":"2024","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.canrad.2025.104778_bib0535","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12893-021-01443-5","article-title":"Risk factors and prognostic significance of lateral pelvic lymph node dissection after neoadjuvant chemoradiotherapy for rectal patients with clinically suspected lateral lymph node metastasis","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Surg"},{"issue":"7","key":"10.1016\/j.canrad.2025.104778_bib0540","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1111\/codi.15670","article-title":"A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer - GRECCAR 15 trial protocol","volume":"23","author":"Denost","year":"2021","journal-title":"Colorectal Dis"},{"issue":"3","key":"10.1016\/j.canrad.2025.104778_bib0545","doi-asserted-by":"crossref","first-page":"zrab029","DOI":"10.1093\/bjsopen\/zrab029","article-title":"Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II)","volume":"5","author":"PelvEx","year":"2021","journal-title":"BJS Open"},{"issue":"1","key":"10.1016\/j.canrad.2025.104778_bib0550","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.clon.2020.06.009","article-title":"Stereotactic pelvic reirradiation for locoregional cancer relapse","volume":"33","author":"Kinj","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"11","key":"10.1016\/j.canrad.2025.104778_bib0555","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068580","article-title":"Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT)","volume":"12","author":"Zhong","year":"2022","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.canrad.2025.104778_bib0560","first-page":"630","article-title":"Reirradiation: standards, challenges, and patient-focused strategies across tumor types","volume":"75","author":"Beddok","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.canrad.2025.104778_bib0565","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s11547-023-01652-3","article-title":"Pattern of care for reirradiation in locally recurrent rectal cancer: a national survey on behalf of the AIRO gastrointestinal tumors study group","volume":"128","author":"Mantello","year":"2023","journal-title":"Radiol Med"},{"issue":"2","key":"10.1016\/j.canrad.2025.104778_bib0570","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1111\/ajco.12185","article-title":"Salvage stereotactic body radiotherapy for locally recurrent uterine cervix cancer at the pelvic sidewall: Feasibility and complication","volume":"12","author":"Seo","year":"2016","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:16:33Z","timestamp":1768738593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825001945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":57,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1278321825001945"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104778","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reirradiation of prostate, gynaecologic and pelvic tumours, suggestions from the Recommendations Commission of the Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104778"}}